BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease

SC0062, a selective endothelin receptor type A (ETA) antagonist developed by BioCity Biopharma, met its primary endpoint in a phase 2 trial for diabetic kidney disease (DKD)13.

The trial, named 2-SUCCEED, demonstrated a significant reduction in proteinuria in the high-dose group (20mg) compared to placebo after 12 weeks of treatment1.

SC0062 showed a favorable safety profile, with no elevated risk of sodium retention compared to placebo13.

Most trial participants were receiving background therapy with SGLT2 inhibitors and RAAS inhibitors1.

SC0062 is designed to be highly selective for ETA over ETB receptors, potentially offering greater efficacy and fewer side effects than non-selective endothelin receptor antagonists13.

The drug has previously shown positive results in a separate cohort of patients with IgA nephropathy (IgAN)3.

BioCity plans to present full 24-week data from the trial at an upcoming scientific conference13.

SC0062 has been granted Breakthrough Therapy Designation by China's National Medical Products Administration for the treatment of IgA Nephropathy with proteinuria1.

A Phase 3 trial (SUCCESS-01) for IgAN is already underway1.

BioCity aims to develop SC0062 for various forms of chronic kidney disease (CKD) globally13.

Sources:

1. https://www.prnewswire.com/news-releases/biocity-announces-its-selective-endothelin-type-a-receptor-antagonist-sc0062-met-the-primary-endpoint-in-diabetic-kidney-disease-dkd-in-a-phase-2-trial-2-succeed-302384313.html

3. https://www.fiercebiotech.com/biotech/biocitys-eta-antagonist-reduces-proteinuria-phase-2-trial-diabetic-kidney-disease